Published Date: September 22, 2023

Full Text Article

A case series on tofacitinib-induced weight gain

Authors: Kanisha Shah, Dhaiwat Shukla, Manish Patel, Supriya Malhotra

Indian J Pharmacol. 2023 Jul-Aug;55(4):263-265. doi: 10.4103/ijp.ijp_158_23.


Janus kinase inhibitor tofacitinib belongs to a group of targeted synthetic disease-modifying anti-rheumatic drugs, also known as small molecule inhibitors. They are oral drugs with a novel strategy to treat inflammatory diseases. The major concern with the use of these drugs is a high risk for infections and other potential side effects. Here, we have focused on reporting one of the rare side effects of tofacitinib, weight gain. We have reported six cases of tofacitinib-induced weight gain in patients of ankylosing spondylitis, rheumatoid arthritis, and vasculitis.

PMID: 37737080DOI: 10.4103/ijp.ijp_158_23PMC: PMC10657621